Literature DB >> 27815599

Tumor segmentation of whole-body magnetic resonance imaging in neurofibromatosis type 1 patients: tumor burden correlates.

Michael A Heffler1, Lu Q Le2, Yin Xi1, Avneesh Chhabra3.   

Abstract

OBJECTIVE: Segmentation of whole-body MRI (WBMRI) to assess the feasibility, quantitate the total tumor volume (tumor burden) in patients with neurofibromatosis type 1 (NF1) and examine associations with demographic, disease-related and anthropomorphic features.
METHODS: A consecutive series of patients with NF1 underwent WBMRI and were reviewed for tumors. Tumors were segmented using a semiautomated software-based tool. Tumors were classified as superficial or deep and discrete or plexiform. Segmentation times were recorded. Segmentation yielded the quantity and tumor burden of superficial, internal and plexiform tumors. Correlations between segmentation data and demographic, disease-related and anthropomorphic features were examined.
RESULTS: Fifteen patients were evaluated (42.3 ± 13.6 years, 10 female, 5 male). Segmentation times were a median of 30 min and yielded 2,328 tumors (1,582 superficial, 746 internal and 23 plexiform). One tumor was malignant. Tumor counts ranged from 14 to 397. Tumor burden ranged from 6.95 cm3 to 571 cm3. Individual tumor volume ranged from 0.0120 cm3 to 298 cm3. Significant correlation was found between the total volume of superficial tumors and height (ρ = 0.5966, p < 0.02). Male patients had higher overall tumor burdens (p < 0.05) and higher superficial tumor burden (p < 0.03). Patients with negative family history had more tumors (p < 0.05).
CONCLUSION: Segmentation of WBMRI in patients with NF1 is feasible and elucidates meaningful relationships among disease phenotype, anthropomorphic and demographic features.

Entities:  

Keywords:  Magnetic resonance imaging; Neurofibromatosis type 1; Segmentation; Tumor burden; Whole-body MRI

Mesh:

Year:  2016        PMID: 27815599     DOI: 10.1007/s00256-016-2522-4

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  12 in total

Review 1.  Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1.

Authors:  R M Reynolds; G G P Browning; I Nawroz; I W Campbell
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

Review 2.  NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update.

Authors:  J J Mulvihill; D M Parry; J L Sherman; A Pikus; M I Kaiser-Kupfer; R Eldridge
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

3.  Progesterone receptor expression in neurofibromas.

Authors:  Margaret E McLaughlin; Tyler Jacks
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

4.  Neurofibromatosis type 1 and pregnancy.

Authors:  L Dugoff; E Sujansky
Journal:  Am J Med Genet       Date:  1996-12-02

5.  Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Authors:  Thorsten Derlin; Katharina Tornquist; Silvia Münster; Ivayla Apostolova; Christian Hagel; Reinhard E Friedrich; Ulrike Wedegärtner; Victor F Mautner
Journal:  Clin Nucl Med       Date:  2013-01       Impact factor: 7.794

Review 6.  Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.

Authors:  J Salamon; V F Mautner; G Adam; T Derlin
Journal:  Rofo       Date:  2015-09-02

7.  Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.

Authors:  Wenli Cai; Ara Kassarjian; Miriam A Bredella; Gordon J Harris; Hiroyuki Yoshida; Victor F Mautner; Ralph Wenzel; Scott R Plotkin
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

8.  Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.

Authors:  Scott R Plotkin; Miriam A Bredella; Wenli Cai; Ara Kassarjian; Gordon J Harris; Sonia Esparza; Vanessa L Merker; Lance L Munn; Alona Muzikansky; Manor Askenazi; Rosa Nguyen; Ralph Wenzel; Victor F Mautner
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

9.  Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients.

Authors:  Marge Lammert; Victor-Felix Mautner; Lan Kluwe
Journal:  BMC Cancer       Date:  2005-02-09       Impact factor: 4.430

10.  Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.

Authors:  Shivani Ahlawat; Laura M Fayad; Muhammad Shayan Khan; Miriam A Bredella; Gordon J Harris; D Gareth Evans; Said Farschtschi; Michael A Jacobs; Avneesh Chhabra; Johannes M Salamon; Ralph Wenzel; Victor F Mautner; Eva Dombi; Wenli Cai; Scott R Plotkin; Jaishri O Blakeley
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.